Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 4.04B 598M 523M 484M 445M 841M 57.69B 855M 5.78B 2.26B 28.18B 2.25B 2.2B 97.22B P/E 2024
217x
P/E 2025 322x
Enterprise Value 4.9B 726M 635M 587M 539M 1.02B 69.97B 1.04B 7.01B 2.75B 34.18B 2.72B 2.66B 118B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.07%
Yield 2024
0.37%
Yield 2025 0.06%
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-23 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-07 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
30/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
26/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
03/07/25 Realcan Pharmaceutical Vice President Detained MT
03/07/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
03/06/25 Yanquan No. 8 Private Securities Investment Fund, a fund managed by Jiaxing Yanquan Investment Partnership LLP cancelled the acquisition of 5.05% stake in Realcan Pharmaceutical Group Co., Ltd. from Zhang Renhua for approximately CNY 160 million. CI
03/06/25 Realcan Pharmaceutical Group Shareholder Nixes Share Transfer Deal MT
1 day+0.73%
1 week+4.17%
Current month+11.79%
1 month+4.17%
3 months-19.83%
6 months-22.10%
Current year-14.60%
1 week 2.61
Extreme 2.61
2.89
1 month 2.38
Extreme 2.38
2.89
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 26/04/2021
President 61 26/05/2023
Corporate Officer/Principal 40 30/10/2019
Director TitleAgeSince
Chairman 61 21/11/2009
Director/Board Member 43 21/11/2009
Chairman 48 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
12/05/23 Sell

Founder

15,000,000 1.2902%
30/03/23 Sell

Founder

13,040,000 1.1260%
30/03/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
+0.73%+4.17%-9.54%-19.12% 592M
-1.18%+3.16%+17.14%+102.31% 98.51B
-1.21%-4.26%+41.48%+144.98% 53.52B
0.00%+3.90%+4.27%+266.25% 23.53B
+1.87%+4.90%-10.85%-18.81% 8.25B
+4.12%+6.67%-30.04%-28.35% 7.79B
+0.28%+5.32%-6.28%-26.28% 6.99B
-0.70%+0.19%+25.69%+30.39% 6.31B
+0.28%+3.05%-0.11%+25.47% 5.51B
+1.17%+3.19%-3.36%-5.97% 3.76B
Average +0.54%+2.00%+2.84%+47.09% 21.48B
Weighted average by Cap. -0.60%+2.17%+17.62%+111.01%

Financials

2024 2025
Net sales 7.97B 1.18B 1.03B 953M 876M 1.66B 114B 1.69B 11.4B 4.46B 55.54B 4.43B 4.33B 192B 7.3B 1.08B 944M 873M 802M 1.52B 104B 1.54B 10.44B 4.09B 50.86B 4.05B 3.97B 175B
Net income 20.62M 3.05M 2.67M 2.47M 2.27M 4.29M 294M 4.36M 29.5M 11.55M 144M 11.46M 11.21M 496M 16.07M 2.38M 2.08M 1.92M 1.77M 3.34M 229M 3.4M 22.99M 9M 112M 8.93M 8.74M 386M
Net Debt 1.6B 236M 206M 191M 175M 332M 22.77B 338M 2.28B 894M 11.12B 886M 867M 38.37B 860M 127M 111M 103M 94.62M 179M 12.28B 182M 1.23B 482M 6B 478M 468M 20.69B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
20/07/26 CN¥2.750 +0.73% 48,910,601
17/07/26 CN¥2.730 -4.21% 55,052,122
16/07/26 CN¥2.850 +0.71% 50,075,359
15/07/26 CN¥2.830 +3.28% 58,591,500
14/07/26 CN¥2.740 +3.40% 49,905,900
  1. Stock Market
  2. Stocks
  3. 002589 Stock